By conducting a comprehensive analysis of existing literature and performing our own experimental studies, we seek to provide insights into the potential therapeutic synergy between FMD and gefitinib, with the ultimate goal of enhancing the therapeutic efficacy of EGFR-targeted treatments in oral cancer. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.